论文部分内容阅读
应用双抗体夹心法对118例晚期肺癌患者血清中可溶性白细胞介素2受体(sIL-2R)进行检测.结果表明,其血清 sIL-2R 水平明显高于正常人(P<0.001)。按 TNM 分期及按病理类型分为鳞癌、腺癌及未分化癌,sIL-2R 水平在Ⅲ、Ⅳ期及各病理类型之间的差异经统计学处理无显著意义。治疗前后患者血清 sIL-2R 的变化表明,凡治疗有反应者 sIL-2R 水平下降,治疗无效者 sIL-2R 水平升高。本研究结果提示 sIL-2R 检测对肺癌诊断、病情观察及预后有参考价值。
The serum levels of sIL-2R in 118 patients with advanced lung cancer were detected by double-antibody sandwich method. The results showed that serum levels of sIL-2R were significantly higher than those in normal subjects (P<0.001). According to TNM stage and pathological type, it was divided into squamous cell carcinoma, adenocarcinoma and undifferentiated carcinoma. The difference between sIL-2R levels in stage III, IV and pathological types was not statistically significant. The change of serum sIL-2R before and after treatment showed that the level of sIL-2R was decreased in those who responded to treatment, and the level of sIL-2R was increased in patients who did not respond to treatment. The results of this study suggest that the sIL-2R test has a reference value for the diagnosis of lung cancer, observation of the disease, and prognosis.